Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia.
Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch PM, Giles HA, Lütge A, Hüllein J, Wagner L, Giacopelli B, Nadeu F, Delgado J, Campo E, Mangolini M, Ringshausen I, Böttcher M, Mougiakakos D, Jacobs A, Bodenmiller B, Dietrich S, Oakes CC, Zenz T, Huber W. Lu J, et al. Among authors: mougiakakos d. Nat Cancer. 2021 Aug;2(8):853-864. doi: 10.1038/s43018-021-00216-6. Epub 2021 Jul 1. Nat Cancer. 2021. PMID: 34423310 Free PMC article.
CAR T-cell perspectives in lupus - Authors' reply.
Schett G, Mackensen A, Mougiakakos D. Schett G, et al. Among authors: mougiakakos d. Lancet. 2024 Jul 27;404(10450):336-337. doi: 10.1016/S0140-6736(24)01266-2. Lancet. 2024. PMID: 39067897 No abstract available.
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
Pugliese GM, Venafra V, Bica V, Massacci G, Latini S, Graziosi S, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F. Pugliese GM, et al. Among authors: mougiakakos d. Leukemia. 2023 May;37(5):1151-1155. doi: 10.1038/s41375-023-01881-5. Epub 2023 Mar 25. Leukemia. 2023. PMID: 36966261 Free PMC article. No abstract available.
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
Massacci G, Venafra V, Latini S, Bica V, Pugliese GM, Graziosi S, Klingelhuber F, Krahmer N, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F. Massacci G, et al. Among authors: mougiakakos d. Leukemia. 2023 Feb;37(2):288-297. doi: 10.1038/s41375-022-01785-w. Epub 2022 Dec 12. Leukemia. 2023. PMID: 36509894 Free PMC article.
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf G, Kröger N, Dreger P. Schubert ML, et al. Among authors: mougiakakos d. Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203. Blood Adv. 2023. PMID: 37603595 Free PMC article. No abstract available.
Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
Zeremski V, McPhail ED, Habermann TM, Schieppati F, Gebauer N, Vassilakopoulos TP, Mougiakakos D. Zeremski V, et al. Among authors: mougiakakos d. Hematol Oncol. 2023 Oct;41(4):776-780. doi: 10.1002/hon.3130. Epub 2023 Mar 21. Hematol Oncol. 2023. PMID: 36945194 No abstract available.
162 results